Unicycive Therapeutics, Inc. Contracts & Agreements
33 Contracts & Agreements
- Business Finance (18 contracts)
- Business Operations (5)
- Human Resources (6)
- Intellectual Property (3)
- Uncategorized (1)
- Manufacturing and Supply Agreement dated as of October 31, 2020 by and between Unicycive Therapeutics, Inc. and Shilpa Medicare Ltd (Filed With SEC on August 14, 2024)
- First Amendment to Manufacturing and Supply Agreement dated June 25, 2024 by and between Unicycive Therapeutics, Inc. and Shilpa Medicare Ltd (Filed With SEC on August 14, 2024)
- Employment Agreement (this Agreement), dated August 12, 2024, by and among Unicycive Therapeutics Inc. and Doug Jermasek (Filed With SEC on August 14, 2024)
- Form of Amended and Restated Tranche A Warrant (Filed With SEC on March 14, 2024)
- Form of Amended and Restated Tranche B Warrant (Filed With SEC on March 14, 2024)
- Form of Amended and Restated Tranche C Warrant (Filed With SEC on March 14, 2024)
- Form of Exchange Agreement, dated March 13, 2024, by and between Unicycive Therapeutics, Inc. and the purchasers named therein (Filed With SEC on March 14, 2024)
- Securities Purchase Agreement, dated March 13, 2024, by and between Unicycive Therapeutics, Inc. and the purchasers named therein (Filed With SEC on March 14, 2024)
- Form of Amendment No. 1 to Securities Purchase Agreement (Filed With SEC on April 10, 2023)
- Form of Specimen Stock Certificate for Series A-1 Preferred Stock (Filed With SEC on March 6, 2023)
- Form of Tranche A Warrant (Filed With SEC on March 6, 2023)
- Form of Tranche B Warrant (Filed With SEC on March 6, 2023)
- Form of Tranche C Warrant (Filed With SEC on March 6, 2023)
- Form of Securities Purchase Agreement, dated March 3, 2023, by and between Unicycive Therapeutics, Inc. and the purchasers named therein (Filed With SEC on March 6, 2023)
- Placement Agency Agreement, dated March 3, 2023 by and between Unicycive Therapeutics, Inc. and EF Hutton, division of Benchmark Investments, LLC (Filed With SEC on March 6, 2023)
- License Agreement effective as of February 1, 2023 by and between Unicycive Therapeutics, Inc. and Lotus International Pte Ltd (Filed With SEC on February 2, 2023)
- License Agreement effective as of July 14, 2022 by and between Unicycive Therapeutics, Inc. and Lees Pharmaceutical (HK) Limited (Filed With SEC on July 18, 2022)
- Description of the Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 31, 2022)
- Form of Underwriting Agreement (Filed With SEC on June 21, 2021)
- Form of Warrant Agent Agreement (including the terms of the Warrant) (Filed With SEC on June 21, 2021)
- Form of Underwriters Unit Purchase Option (Filed With SEC on June 21, 2021)
- Form of Underwriting Agreement (Filed With SEC on June 7, 2021)
- 2018 Equity Incentive Plan (Filed With SEC on June 7, 2021)
- 2019 Stock Option Plan (Filed With SEC on June 7, 2021)
- Assignment and Asset Purchase Agreement by and between the Company and Spectrum Pharmaceuticals, Inc., dated September 20, 2018 (Filed With SEC on June 7, 2021)
- Exclusive License Agreement by and between the Company and Sphaera Pharma Pte. Ltd., dated October 1, 2017 (Filed With SEC on June 7, 2021)
- Service Agreement by and between the Company and Globavir Biosciences, Inc. dated July 1, 2017 (Filed With SEC on June 7, 2021)
- Specimen Stock Certificate evidencing the shares of common stock (Filed With SEC on May 21, 2021)
- 2021 Omnibus Equity Incentive Plan (Filed With SEC on May 21, 2021)
- Employment Agreement by and between the Company and Shalabh Gupta, M.D., dated May 18, 2021 (Filed With SEC on May 21, 2021)
- Employment Agreement by and between the Company and Pramod Gupta, M.D., dated March 22, 2021 (Filed With SEC on May 21, 2021)
- Amendment to Employment Agreement by and between the Company and Pramod Gupta, M.D., dated April 28, 2021 (Filed With SEC on May 21, 2021)
- Master Services Agreement, dated February 8, 2021, by and between Unicycive Therapeutics, Inc. and Ascent Development Services, Inc (Filed With SEC on May 21, 2021)
